EUCTR2008-000585-22-DE进行中（未招募）不适用
An Open-Label, Multi-Centre, Uncontrolled, Exploratory Study, Investigating Degarelix One-Month Dosing Regimen as Second-Line Hormonal Treatment after PSA-Failure in GnRH Agonist Treated Patients with Prostate Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Patient has given written informed consent before any trial-related activity is performed.
- •2. Patient is 18 years or older.
- •3. Histologically confirmed prostate cancer.
- •4. Patient has received GnRH receptor agonist therapy for a duration of at least 12 months (the first dose of GnRH-antagonist is to be administered when the next dose of the GnRH-agonist would have been due).
- •5. Patient has experienced rising PSA levels although receiving GnRH agonist therapy, defined as two consecutive rises of PSA at least two weeks apart in two 50% increases over the nadir, and at least one PSA value of >2.5 ng/mL within the last six months.
- •6. Testosterone =0.32 ng/mL at inclusion
- •7. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
- •8. Estimated life expectancy at least 12 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous history or presence of another malignancy, other than prostate cancer or treated squamous / basal cell carcinoma of the skin, within the last five years.
- •2. Ongoing GnRH agonist therapy (last dose of previous GnRH agonist must have been received before Visit 1).
- •3. Any pre-trial secondary hormonal manipulation (including antiandrogens) after PSA increase as described as above and before trial entry. Antiandrogens as part of complete androgen blockade must have been discontinued at least three months before first dose of trial medication.
- •4. Previous or current treatment with chemotherapy (e.g. estramustine) for prostate cancer.
- •5. Known hypersensitivity towards any component of the investigational medical product.
- •6. History of severe uncontrolled asthma, anaphylactic reactions, or severe urticaria and/or angioedema.
- •7. Known or suspected clinically significant liver and/or biliary disease.
- •8. Any clinically significant laboratory abnormalities, disorders, or other condition, including alcohol or drug abuse, which may affect the patient's health or the outcome of the trial as judged by the Investigator.
- •9. Patient has a clinically significant disorder (other than prostate cancer) including, but not limited to, renal, hematological, gastrointestinal, endocrine, cardiac, neurological, or psychiatric disease, and alcohol or drug abuse or any other condition, which may affect the patient's health or the outcome of the trial as judged by the Investigator.
- •10. Patient has a mental incapacity or language barriers precluding adequate understanding or co-operation.
- •11. Patient has received an investigational drug within the last 28 days preceding screening visit. Or longer if considered to possibly influencing the outcome of the current trial.
- •12. Previous participation in any degarelix trial.
研究者
相似试验
招募中
2 期
A exploratory clinical trial to evaluate the efficacy on sleep during repeated exposure to lavender in the elderly subjectsJPRN-jRCT1061220100Iwata Masaaki12
进行中（未招募）
不适用
A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-Cell /Antibody response panel to predict the clinical effect of Octagam 5% in subjects with relapsing/remitting (RR) multiple sclerosis (MS)Subjects with RR Multiple Sclerosis in whom intravenous immunoglobulin (IVIG) treatment is clinically indicated because first-line treatments are contraindicated or not tolerated.EUCTR2008-004579-22-ATOctapharma AG30
已完成
不适用
A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg assay panel and the B-Cell/antibody response panel to predict the clinical effect of Octagam® 5% in subjects with relapsing/remitting multiple sclerosisMultiple sclerosisNervous System DiseasesISRCTN57377482Octapharma AG (Switzerland)30
进行中（未招募）
不适用
A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-cell/Antibody Response Panel to predict the clinical efefct of Octagam 5% in subjects with relapsing/remitting Multiple SclerosisSubjects with RR Multiple Sclerosis in whom intravenous immunoglobulin (IVIG) treatment is clinically indicated because first-line treatments are contraindicated or not tolerated.MedDRA version: 9.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2008-004579-22-DEOctapharma AG30
尚未招募
Unknown
A study to confirm the detection rate of EGFR T790M in bronchial washings of non-small cell lung cancer patients and the therapeutic effect of Lecraza® in T790M positive patientsKCT0009390Yonsei University Health System, Gangnam Severance Hospital40